Corient Private Wealth
GLUE icon

Corient Private Wealth’s Monte Rosa Therapeutics GLUE Stock Holding History

Corient Private Wealth’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$311K Buy
+18,906
New +$362K ﹤0.01% 2308

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Corient Private Wealth's GLUE Position: Q1 2026 in Review

Corient Private Wealth opened a new position in Monte Rosa Therapeutics (GLUE) in Q1 2026: 18,906 shares worth $311K. The stake represents ﹤0.01% of the portfolio and ranks #2308 among its holdings.

190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Corient Private Wealth held 18,906 shares of Monte Rosa Therapeutics worth $311K as of Q1 2026.
  • Monte Rosa Therapeutics was a new Corient Private Wealth position in Q1 2026.
  • Monte Rosa Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q1 2026, its #2308 holding.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.